GLP-1 Agents May Reduce Psoriasis Severity - Summary - MDSpire
From the Journals

GLP-1 Agents May Reduce Psoriasis Severity

National Psoriasis Foundation review highlights limited evidence and potential metabolic links

  • By

  • Andrea Surnit

  • May 5, 2026

  • 4 min

Share

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may help reduce the severity of psoriasis in patients with metabolic conditions, according to a review from the National Psoriasis Foundation Medical Board published in JAMA Dermatology. Evidence suggests significant reductions in Psoriasis Area and Severity Index (PASI) scores, particularly in obese patients with type 2 diabetes. However, findings vary across studies, with concerns about sample size and study design. Although GLP-1 RAs are not approved for psoriasis treatment, their potential as adjunctive therapy is acknowledged.

Original Source(s)

GLP-1 Agents May Reduce Psoriasis Severity

  • by Andrea Surnit

  • May 5, 2026

Related Content

May JADA evaluates ability of automated testing platform to detect HPV in saliva

The study compared the abilities of an automated testing platform and conventional testing techniques to detect HPV.

AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation

In a systematic review and meta-analysis published in JAMA Dermatology, Laiouar-Pedari et al evaluated the real-world diagnostic performance of artificial intelligence (AI)–assisted dermoscopy for mel...

  • May 4, 2026

  • 3 min
CLL Linked to Increased Skin Cancer Risk and Mortality

In a nationwide population–based cohort study reported in JAMA Dermatology, Blomberg Drejøe et al evaluated the long-term risk of skin cancer and related outcomes among patients with chronic lymphocyt...